Valuable Targets

What are C5 inhibitors and how do you quickly get the latest development progress?

15 November 2023
4 min read

C5, or the fifth component of complement, plays a crucial role in the human body's immune system. It is a protein that is part of the complement system, a group of proteins that work together to defend against infections and promote inflammation. C5 is involved in the activation of the complement cascade, which leads to the destruction of foreign pathogens, such as bacteria and viruses. Additionally, C5 is also implicated in various inflammatory diseases and disorders, making it an important target for pharmaceutical interventions aimed at modulating the immune response and treating related conditions.

C5 complement inhibitors are protease complexes in the complement system that can defend against biological invasion. C5 complement inhibitors can prevent complement cascade reactions at the C5 level and can prevent diseases caused by immune responses. C5 complement inhibitors can also maintain the production of C3b, which is crucial for the normal phagocytic process of clearing circulating immune complexes and bacterial and fungal pathogens. Because the indications for complement C5 inhibitors are very broad, they can solve diseases caused by a disrupted complement system, and thus have huge market potential.

The current competitive landscape of target C5 is characterized by the presence of multiple companies with diverse R&D pipelines. AstraZeneca PLC stands out as the company with the most advanced R&D progress, with drugs in various phases of development. The highest stage of development on this target is the Approved phase, with a focus on indications such as Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome, and AQP4-IgG positive Neuromyelitis optica spectrum disorder. Monoclonal antibodies are the most common drug type, indicating intense competition in this area. The United States, European Union, and Japan are the leading countries/locations in terms of drug development under target C5, with China also making progress in this field. Overall, target C5 shows a promising future with a diverse range of companies, indications, drug types, and global development.

How do they work?

C5 inhibitors are a type of medication that target and inhibit the activity of the complement protein C5. The complement system is a part of the immune system that helps to identify and eliminate foreign substances, such as bacteria and viruses. However, in certain conditions, the complement system can become overactive and cause damage to healthy tissues.

C5 inhibitors specifically block the action of the C5 protein, preventing it from initiating the formation of the membrane attack complex (MAC). The MAC is a group of proteins that can form pores in the membranes of target cells, leading to their destruction. By inhibiting C5, these inhibitors can help reduce inflammation, tissue damage, and the overall immune response.

In the context of biomedicine, C5 inhibitors are primarily used in the treatment of complement-mediated diseases, such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and certain types of autoimmune disorders. These inhibitors can help manage the symptoms, prevent organ damage, and improve the quality of life for individuals with these conditions.

It's important to note that C5 inhibitors are typically prescribed and administered under the guidance of healthcare professionals, as they may have potential side effects and require careful monitoring.

List of C5 Inhibitors

The currently marketed C5 inhibitors include:

For more information, please click on the image below.

图形用户界面, 应用程序

描述已自动生成What are C5 inhibitors used for?

The highest stage of development on C5 inhibitors is the Approved phase, with a focus on indications such as Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome, and AQP4-IgG positive Neuromyelitis optica spectrum disorder. For more information, please click on the image below to log in and search.

图片包含 日程表

描述已自动生成

How to obtain the latest development progress of C5 inhibitors?

In the Synapse database, you can keep abreast of the latest research and development advances of C5 inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 表格

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

KRASG12D-LODER: brief review of its R&D progress and the clinical result in 2023 ESMO
ESMO 2023
3 min read
KRASG12D-LODER: brief review of its R&D progress and the clinical result in 2023 ESMO
15 November 2023
On October 20, 2023, a novel extended-release siRNA targeting KRASG12D/V (G12D/V) mutations (Loder) in combination with standard chemotherapy was reported at the ESMO Congress.
Read →
Qualigen Therapeutics announces first dose of Phase 1a QN-302 Clinical Study for advanced solid tumors administered to initial patient
Latest Hotspot
3 min read
Qualigen Therapeutics announces first dose of Phase 1a QN-302 Clinical Study for advanced solid tumors administered to initial patient
15 November 2023
Qualigen Therapeutics reports the initial dosage in the Phase 1a QN-302 Clinical Study for Advanced or Metastatic Solid Tumors has been administered to the first patient.
Read →
What are BTK inhibitors and how do you quickly get the latest development progress?
What are BTK inhibitors and how do you quickly get the latest development progress?
15 November 2023
Bruton's Tyrosine Kinase (BTK) inhibitors present a promising treatment for B-cell malignancies. Over the past decade, numerous clinical trials involving BTK inhibitors with anticancer potential have commenced, signaling a bright future for BTK inhibitors.
Read →
Endostar: Brief Review of its R&D progress and the clinical result in 2023 ESMO
ESMO 2023
4 min read
Endostar: Brief Review of its R&D progress and the clinical result in 2023 ESMO
15 November 2023
On 23 Oct 2023, the results from a phase II trial of endostar in patients with locally advanced squamous cell carcinoma of esophagus were reported at the ESMO Congress.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.